1. Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies 
Srinivas R. Nalamachu, MD, Michael Kutch, MS, Martin E. Hale, MD 
Journal of Pain and Symptom Management 
Volume 44, Issue 6, Pages (December 2012)
DOI: /j.jpainsymman
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Once-daily hydromorphone ER safety analysis population (opioid-tolerant patients only). *Of the 979 total patients included in the uncontrolled study pool, 687 patients were unique (Study DO-109 included patients who had participated in DO-104 and DO-105, and Study DO-127X included patients who had participated in Study DO-127). Of these 687 patients, 100 also are represented in the total of 664 patients in the controlled study pool because of their participation in a controlled primary study before an uncontrolled extended study (Study DO-109 also included patients who had participated in DO-119, and Study DO-118X included patients who participated in DO-118). Therefore, 1251 unique patients were included across all studies ( ).
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions